OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
AGPU$5.5557

Axe Compute Inc

Biotechnology & Medical ResearchVerified

Axe Compute Inc exhibits a highly leveraged equity structure, with a market price of $5.55 per share and a market capitalization of $30.74 million. The company's price-to-book ratio of 0.64 suggests that the market values the company at a discount to its book value, while the price-to-tangible-book ratio is identical, indicating no intangible asset premium. The enterprise value to revenue ratio of 246.26 is significantly higher than typical industry benchmarks, reflecting a high valuation relative to its current revenue base. Profitability metrics for Axe Compute Inc are deeply negative, with a return on equity of -4.885% and a return on assets of -4.4073%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets. The operating income of -$180.92 million and net income of -$233.10 million further underscore the company's financial distress. The gross profit margin of 42.03% is relatively high, but this is offset by substantial operating and non-operating expenses. Geographically and segment-wise, Axe Compute Inc's revenue concentration is not explicitly detailed in the available data. However, the company's operations are primarily focused on healthcare diagnostics, with no significant diversification across business lines or regions. This lack of diversification could expose the company to sector-specific risks, particularly in the biotechnology and medical research fields. The company's growth trajectory is concerning, with a significant decline in operating cash flow of -$9.96 million and a free cash flow of -$265.35 million. The capital expenditure of -$32.62 million indicates a heavy investment in infrastructure, which may not be yielding positive returns at this time. The outlook for the current fiscal year is negative, with no clear signs of improvement in the near term. Risk factors for Axe Compute Inc include a medium liquidity risk, as indicated by the current ratio of 10.02, which suggests the company has sufficient current assets to cover its current liabilities. However, the company's net cash position is negative after accounting for total debt, which could pose a liquidity challenge. The dilution risk is currently low, but the company's financial performance and capital structure may change this outlook in the future. Recent events and filings indicate that Axe Compute Inc is facing significant financial challenges, with a last actual EPS of -$34.80 and a last actual revenue of $1.624 million. These figures highlight the company's struggle to generate positive earnings and revenue, which could impact investor confidence and future funding opportunities.

30-day price · AGPU(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyAxe Compute Inc
TickerAGPU.O
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
AI analysis

Business. Axe Compute Inc is a biotechnology company focused on healthcare diagnostics, primarily generating revenue through the development and commercialization of diagnostic solutions.

Classification. Axe Compute Inc is classified under the Healthcare sector, specifically in the Biotechnology & Medical Research industry, with a high confidence level of 0.92 based on verified market data.

Axe Compute Inc exhibits a highly leveraged equity structure, with a market price of $5.55 per share and a market capitalization of $30.74 million. The company's price-to-book ratio of 0.64 suggests that the market values the company at a discount to its book value, while the price-to-tangible-book ratio is identical, indicating no intangible asset premium. The enterprise value to revenue ratio of 246.26 is significantly higher than typical industry benchmarks, reflecting a high valuation relative to its current revenue base. Profitability metrics for Axe Compute Inc are deeply negative, with a return on equity of -4.885% and a return on assets of -4.4073%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets. The operating income of -$180.92 million and net income of -$233.10 million further underscore the company's financial distress. The gross profit margin of 42.03% is relatively high, but this is offset by substantial operating and non-operating expenses. Geographically and segment-wise, Axe Compute Inc's revenue concentration is not explicitly detailed in the available data. However, the company's operations are primarily focused on healthcare diagnostics, with no significant diversification across business lines or regions. This lack of diversification could expose the company to sector-specific risks, particularly in the biotechnology and medical research fields. The company's growth trajectory is concerning, with a significant decline in operating cash flow of -$9.96 million and a free cash flow of -$265.35 million. The capital expenditure of -$32.62 million indicates a heavy investment in infrastructure, which may not be yielding positive returns at this time. The outlook for the current fiscal year is negative, with no clear signs of improvement in the near term. Risk factors for Axe Compute Inc include a medium liquidity risk, as indicated by the current ratio of 10.02, which suggests the company has sufficient current assets to cover its current liabilities. However, the company's net cash position is negative after accounting for total debt, which could pose a liquidity challenge. The dilution risk is currently low, but the company's financial performance and capital structure may change this outlook in the future. Recent events and filings indicate that Axe Compute Inc is facing significant financial challenges, with a last actual EPS of -$34.80 and a last actual revenue of $1.624 million. These figures highlight the company's struggle to generate positive earnings and revenue, which could impact investor confidence and future funding opportunities.
Key takeaways
  • Axe Compute Inc is operating at a significant loss, with a net income of -$233.10 million and a return on equity of -4.885%.
  • The company's market valuation is high relative to its revenue, with an enterprise value to revenue ratio of 246.26.
  • The company's liquidity position is medium, with a current ratio of 10.02, but it has a negative net cash position after accounting for total debt.
  • Axe Compute Inc's growth trajectory is negative, with a substantial decline in operating and free cash flow.
  • The company's financial performance and capital structure may increase dilution risk in the future.
  • Recent financial filings indicate a significant decline in earnings and revenue, which could impact investor confidence.
  • --
  • ## RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$125.3k
Gross profit$52.7k
Operating income-$180.9M
Net income-$233.1M
R&D
SG&A
D&A
SBC
Operating cash flow-$10.0M
CapEx-$32.6M
Free cash flow-$265.3M
Total assets$52.9M
Total liabilities$5.2M
Total equity$47.7M
Cash & equivalents
Long-term debt$108.0k
Valuation
Market price$5.55
Market cap$30.7M
Enterprise value$30.9M
P/E
Reported non-GAAP P/E
EV/Revenue246.3
EV/Op income
EV/OCF
P/B0.6
P/Tangible book0.6
Tangible book$47.7M
Net cash-$108.0k
Current ratio10.0
Debt/Equity0.0
ROA-4.4%
ROE-4.9%
Cash conversion4.0%
CapEx/Revenue-260.4%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Diagnostics · cohort 170 companies
MetricAGPUActivity
Op margin-144409.1%-227.5% medp25 -1250.6% · p75 -3.5%bottom quartile
Net margin-186059.4%-194.5% medp25 -1233.8% · p75 0.8%bottom quartile
Gross margin42.0%53.0% medp25 25.9% · p75 75.7%below median
CapEx / revenue-26035.1%-8.2% medp25 -35.2% · p75 -2.5%bottom quartile
Debt / equity0.0%1.2% medp25 0.0% · p75 17.4%bottom quartile
Observations
IR observations
Last actual EPS-34.80 USD
Last actual revenue1,624,000 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-16 23:55 UTC#d5d8cabe
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 07:06 UTCJob: 94a49e32